Clinical lung cancer最新文献

{"title":"Lung Carcinoid Tumors With Potentially Actionable Genomic Alterations and Responses to Targeted Therapies.","authors":"Sarah Waliany, Yin P Hung, Fawzi Abu Rous, Faustine Luo, Marzia Capelletti, Steven Ressler, Andrew Do, Jennifer Peterson, Caitlin Meservey, Subba R Digumarthy, Sai-Hong Ignatius Ou, Shirish M Gadgeel, Jessica J Lin, Catherine B Meador","doi":"10.1016/j.cllc.2025.03.009","DOIUrl":"https://doi.org/10.1016/j.cllc.2025.03.009","url":null,"abstract":"<p><strong>Background: </strong>Effective treatments for patients with advanced lung carcinoids remain limited. The prevalence of potentially actionable genomic alterations (AGAs) among lung carcinoids is not well-understood.</p><p><strong>Materials and methods: </strong>Lung carcinoids submitted for next-generation sequencing (NGS) at a Clinical Laboratory Improvement Amendments (CLIA)-certified genomics laboratory from September 2013 to March 2024 were retrospectively investigated to determine prevalence of AGAs. We evaluated outcomes with genotype-matched targeted therapies in patients with advanced lung carcinoids with AGAs identified across 3 institutions and comprehensive literature search.</p><p><strong>Results: </strong>Among 321 cases of lung carcinoids profiled by NGS, 8 (2.5%) harbored potential AGAs (4 [1.2%] with commercially available targeted therapies), including KRAS mutations (n = 4, 1.2%: G12C, G12D, G12R, G12V), ALK fusions (n = 2, 0.6%), BRAF D594N (n = 1, 0.3%), and RET fusion (n = 1, 0.3%). None of the 24 typical carcinoids harbored an AGA. Collectively across these database-identified patients, our multi-institutional cohort, and literature review, we identified 36 cases of lung carcinoids with potential AGAs (24 with commercially available targeted therapies), predominantly comprising fusions of ALK (n = 14), RET (n = 5), and NTRK (n = 2). Of 27 with known disease stage, 19 had stage 4 disease, and 13 (68.4%) had outcomes reported following targeted therapies. Median treatment duration was 12.0 months (95% CI: 6.7-16.0). Median progression-free survival (PFS) was 10.6 months (95% CI: 6.7-16.0) across all targeted therapy lines and 14.0 months (95% CI: 1.3-NA) with first-line targeted therapies. Objective response rate with at least one targeted therapy was 61.5%.</p><p><strong>Conclusions: </strong>Patients with advanced lung carcinoids harboring AGAs can derive meaningful benefit from genotype-matched targeted therapies, highlighting potential role for NGS in patients with advanced carcinoids.</p>","PeriodicalId":10490,"journal":{"name":"Clinical lung cancer","volume":" ","pages":""},"PeriodicalIF":3.3,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143985952","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Brief Report: The Effectiveness of Osimertinib in Advanced Nonsmall Cell Lung Cancer Harboring Various EGFR Exon 19 Mutation Variants.","authors":"Lih-Chyun Chang, Hsiang-Wei Hu, Min-Shu Hsieh, Shang-Gin Wu, Jin-Yuan Shih","doi":"10.1016/j.cllc.2025.03.008","DOIUrl":"https://doi.org/10.1016/j.cllc.2025.03.008","url":null,"abstract":"","PeriodicalId":10490,"journal":{"name":"Clinical lung cancer","volume":" ","pages":""},"PeriodicalIF":3.3,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143990739","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Systematic Review for the Follow-up of Curatively Treated Patients With Lung Cancer.","authors":"Yaron Shargall, Emily T Vella, Maria Elisabeth Del Giudice, Carole Dennie, Peter M Ellis, Swati Kulkarni, Robert MacRae, Yee C Ung","doi":"10.1016/j.cllc.2025.03.003","DOIUrl":"https://doi.org/10.1016/j.cllc.2025.03.003","url":null,"abstract":"<p><strong>Introduction: </strong>The follow-up of patients with lung cancer after curative-intent treatment should include strategies to improve their quality of life and survival. These could include the monitoring and management of symptoms of recurrence and late toxicities from cancer treatments, the use of patient-reported outcome (PRO) tools, and smoking cessation interventions. The objective of this systematic review was to examine these follow-up strategies.</p><p><strong>Materials and methods: </strong>This systematic review was developed by Ontario Health (Cancer Care Ontario)'s Program in Evidence-Based Care. MEDLINE, EMBASE, and the Cochrane Library were searched for systematic reviews and randomized controlled trials (RCTs) comparing different types of clinicians, PRO tools, smoking cessation interventions, and management strategies for signs, symptoms, risk factors, comorbidities, or late toxicities in adult patients with NSCLC or SCLC after curative-intent treatment.</p><p><strong>Results: </strong>Thirty-five RCTs and nineteen systematic reviews were included. For nurse-led interventions, either significant effects were found in favor of the intervention, or no significant effects were found. The results for the use of PRO tools were mixed, possibly due to differences in comparators and settings. Evidence suggested that smoking cessation interventions might benefit these patients (RR, 0.84; 95% CI, 0.68-1.03). There was limited evidence in the target population for the management of signs, symptoms, risk factors, comorbidities, or late toxicities.</p><p><strong>Conclusions: </strong>Smoking cessation interventions, exercise training, and the use of PRO tools may benefit these patients. The results of this systematic review were used to inform recommendations in a clinical practice guideline. Further RCTs in this patient population are needed.</p>","PeriodicalId":10490,"journal":{"name":"Clinical lung cancer","volume":" ","pages":""},"PeriodicalIF":3.3,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143991473","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictors of Up-To-Date Lung Cancer Screening Among Eligible People in the United States: A Nationally Representative Dataset.","authors":"Safa Elkefi, Erica Phillips, Lauren K Groner, Alicia K Matthews","doi":"10.1016/j.cllc.2025.03.005","DOIUrl":"https://doi.org/10.1016/j.cllc.2025.03.005","url":null,"abstract":"<p><p>This study examines the factors associated with up-to-date lung cancer screening (UTD-LCS) among eligible adults. We analyzed survey data from the 2022 Behavioral Risk Factor Surveillance System (BRFSS) and selected participants eligible for LCS. Logistic regression models were used to examine the relationship between UTD-LCS and various factors, including demographics, mental and physical health, and access to healthcare. Among the respondents (Weighted N = 13,037,747), 8.18% were eligible for LCS. However, only 24.53% of those eligible had undergone screening in the past year. Individuals who self-identified as Asian (OR = 0.77, P = .008), American Indian (OR = 0.78, P = .002), and Hispanic (OR = 0.79, P = .006) were significantly less likely to participate in LCS screening. In contrast, married individuals (OR = 1.07, P = .019) and older adults aged 70 to 80 years (OR = 1.78, P < .001) were more likely to have undergone screening. Additionally, a poor physical health status was associated with UTD-LCS, as having more days of poor health increased the odds of screening (for 14 days or more: OR = 1.28, P < .001). Finally, having insurance (private plan: OR = 3.7, P < .001) and not experiencing medical cost issues (OR = 1.13, P = .025) were also associated with greater odds of being up-to-date on lung cancer screening. Our results underscore the need for targeted public health interventions that increase awareness and accessibility of LCS. The study also emphasizes the critical role of primary care providers in promoting screening.</p>","PeriodicalId":10490,"journal":{"name":"Clinical lung cancer","volume":" ","pages":""},"PeriodicalIF":3.3,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143977825","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genetic Ancestry and Lung Cancer in Latin American Patients: A Crucial Step for Understanding a Diverse Population.","authors":"Juan Pablo Castañeda-González, Rafael Parra-Medina, Jonathan W Riess, David R Gandara, Luis G Carvajal-Carmona","doi":"10.1016/j.cllc.2025.03.004","DOIUrl":"https://doi.org/10.1016/j.cllc.2025.03.004","url":null,"abstract":"<p><p>Lung cancer is the second leading cause of cancer-related deaths in Latin America. While incidence and mortality rates are higher in other populations, the ``Hispanic paradox'' observed in US Hispanics reflects a lower mortality rate for mortality from non-small cell lung cancer (NSCLC) despite socioeconomic disparities, which may be related to epigenetic and cultural factors. Genetic studies have identified single nucleotide polymorphisms associated with ancestry as key contributors to lung cancer risk and outcomes, emphasizing the importance of genomic insights for early detection and personalized treatments. This narrative review explores the impact of genetic ancestry on lung cancer in Hispanic/Latino populations. We searched MEDLINE and Google Scholar for \"((SNP) OR (germline) OR (variant)) AND (lung cancer) AND ((Hispanic) OR (Latin)),\" focusing on Latin American studies. We included articles published up to December 2024. Specific variation in genes such as XRCC1, CYP1A1, CYP1A2, SEMA3B, PADPRP, and mEPHX have been associated with increased lung cancer risk. Lung cancer incidence and prognosis vary significantly among Hispanics due to their diverse genetic ancestry. Understanding ancestry-specific genetic variations may help personalize treatment and improve outcomes for this population.</p>","PeriodicalId":10490,"journal":{"name":"Clinical lung cancer","volume":" ","pages":""},"PeriodicalIF":3.3,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143961540","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Longitudinal Analysis of Recurrence and Risk Factors of Early-Stage Resected Adenocarcinoma With Common EGFR Mutations: A Multicenter Retrospective Cohort Study in South Korea.","authors":"June Hong Ahn, Sun Ha Choi, Sun Hyo Park, Insu Kim, Jin Han Park, Ji Yeon Kim, Tae Hoon Kim, Taehoon Lee, Hyun Kyu Cho, Jong Hwan Jeong, Jung Wook Yang, Ji Eun Park, Tae Hun Kim, Hyun-Kyung Lee, Ho Young Lee, Ho Jin Jung, Jinmi Kim, Jungmin Son, Jung Seop Eom","doi":"10.1016/j.cllc.2025.02.016","DOIUrl":"https://doi.org/10.1016/j.cllc.2025.02.016","url":null,"abstract":"<p><strong>Introduction: </strong>Despite curative surgery for lung cancer, 30% to 55% of patients experience recurrence or death, which highlights the importance of adjuvant treatment. Adjuvant osimertinib therapy effectively prolongs disease-free and overall survival in patients with lung cancer harboring common epidermal growth factor receptor (EGFR) mutations. To identify potential candidates for adjuvant osimertinib, it is crucial to understand the rates and identify risk factors of recurrence.</p><p><strong>Methods: </strong>This multicenter, retrospective cohort study was conducted in the Republic of Korea and enrolled patients who, between 2010 and 2017, underwent resection of stages I-III adenocarcinomas, with common EGFR mutations. The primary outcomes comprised the rate and risk factors of postoperative recurrence.</p><p><strong>Results: </strong>Among the 759 participants, the overall recurrence rate and median recurrence-free survival were 39.1% and 59.8 (interquartile range [IQR], 26.3-84.2) months, respectively, during a median follow-up of 73.0 (IQR, 55.4-95.0) months. The recurrence rates for stages IA, IB, IIA, IIB, IIIA, and IIIB were 14.7%, 45.5%, 53.8%, 72.5%, 80.3%, and 93.3%, respectively. Multivariate analysis revealed that age ≥ 65 years, body mass index < 18.5 kg/m², the Del19 subtype of EGFR mutation, tumor size ≥ 2.3 cm, N1 involvement, N2 involvement, predominantly micropapillary or solid pattern, and the presence of visceral pleural invasion were independently associated with recurrence.</p><p><strong>Conclusion: </strong>This multicenter cohort study demonstrated that stages I-III EGFR-mutated adenocarcinoma has a postoperative recurrence rate of 39.1%, and identified 7 independent risk factors for recurrence.</p>","PeriodicalId":10490,"journal":{"name":"Clinical lung cancer","volume":" ","pages":""},"PeriodicalIF":3.3,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143742505","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"First-Line Pembrolizumab Efficacy in Octogenarians With NSCLCs Expressing ≥ 50% PD-L1 (ESCKEYP GFPC 05-2018).","authors":"Romain Corre, Chantal Decroisette, Jean-Bernard Auliac, Lionel Falchero, Hubert Curcio, Karim Amrane, Maurice Perol, Stéphane Hominal, Sabine Vieillot, Eric Huchot, Anne Laure Desage, Marie Bernardi, Remi Veillon, Hélène Doubre, Suzanna Bota, Gwenaelle Legarff, Grégoire Justeau, Oliver Bylicki, Magali Roa, Renaud Descourt, Christos Chouaïd, Laurent Greillier","doi":"10.1016/j.cllc.2025.03.001","DOIUrl":"https://doi.org/10.1016/j.cllc.2025.03.001","url":null,"abstract":"<p><strong>Background: </strong>Pembrolizumab alone is a first-line therapeutic option for patients with metastatic non-small cell lung cancer (NSCLC) with ≥ 50% PD-L1 expression, but few data are available for elderly patients, specifically octogenarians.</p><p><strong>Methods: </strong>This retrospective, multicenter study included all consecutive patients with metastatic NSCLC PD-L1 ≥ 50% treated with first-line pembrolizumab monotherapy between May 2017 and November 2019. Information was collected from medical files with local evaluation of therapeutic response and progression-free survival (PFS).</p><p><strong>Results: </strong>Among the 844 patients included, 73 (8.4%) were ≥ 80 (median: 82) years old, 74% men, 23.3% with ECOG-PS ≥ 2, 26% had ≥ 5% weight loss, PD-L1 50%-75%/≥ 75%: 45.2%/46.6%, respectively, with significantly more nonsmokers and (17.4% vs. 5.6%, P = .0002) and fewer adenocarcinomas (57.5% vs. 70.8%, P = .0217) than those < 80 years. After median follow-up of 45.7 (95% CI: 43.0-49.1) months, respective median overall survival (OS) for octogenarians versus younger patients lasted 12.0 (95% CI: 7.7-16.2) versus 23.9 (95% CI: 19.5-27.4) months (P = .0002), and median PFS for 5.0 (95% CI: 2.8-9.2) versus 8.3 (95% CI: 7.2-9.8) months (P = .039). Their respective objective response rates did not differ significantly: 42% (95% CI: 24-60) vs. 49% (95% CI: 43-54).</p><p><strong>Conclusions: </strong>Based on the results of this large multicenter population, first-line pembrolizumab efficacy against NSCLCs expressing ≥ 50% PD-L1 in octogenarians seems inferior to that obtained in younger patients. The higher percentage of nonsmokers and fewer adenocarcinomas could partially explain that finding.</p>","PeriodicalId":10490,"journal":{"name":"Clinical lung cancer","volume":" ","pages":""},"PeriodicalIF":3.3,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143691128","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Role of GLP-1 Agonists in Mitigating Lorlatinib-Induced Metabolic Syndrome: Two Case Studies.","authors":"Erica Pietroluongo, Silvana Pannain, Marina Chiara Garassino, Christine M Bestvina","doi":"10.1016/j.cllc.2025.03.002","DOIUrl":"https://doi.org/10.1016/j.cllc.2025.03.002","url":null,"abstract":"","PeriodicalId":10490,"journal":{"name":"Clinical lung cancer","volume":" ","pages":""},"PeriodicalIF":3.3,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143742506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unmet Needs in Maintenance Therapy for Extensive Stage Small Cell Lung Cancer","authors":"Luis Paz-Ares ,&nbsp;Brinda Gupta ,&nbsp;Javier Baena ,&nbsp;Stephen V. Liu","doi":"10.1016/j.cllc.2025.02.015","DOIUrl":"10.1016/j.cllc.2025.02.015","url":null,"abstract":"<div><div>Small cell lung cancer (SCLC) is a highly aggressive malignancy and an exceptionally lethal disease; most patients present with extensive stage (ES) disease at diagnosis. Very little had changed in the treatment of ES-SCLC for decades until immune checkpoint inhibitor (ICI) therapy combined with chemotherapy followed by ICI maintenance monotherapy was added to standard treatment paradigms in 2019. Despite this important advance, high rates of relapse are still observed in patients with ES-SCLC and long-term survival rates remain low, with approximately 40% of patients proceeding to receive second-line treatment. There is an urgent need for novel treatment strategies to improve patient outcomes. In this review, we describe the rationale for maintenance therapy approaches in ES-SCLC and summarize the existing data on chemotherapy, ICIs, and other agents in the first-line maintenance setting. Predictive biomarkers, SCLC subtypes, and new therapeutics in development are discussed including lurbinectedin, antibody-drug conjugates, and T-cell engager molecules.</div></div>","PeriodicalId":10490,"journal":{"name":"Clinical lung cancer","volume":"26 3","pages":"Pages 168-178"},"PeriodicalIF":3.3,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143742432","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Young Onset Lung Cancer in India: Insights Into Clinical, Demographic, and Genomic Profiles.","authors":"Prabhat Singh Malik, Neha Pathak, Aparna Sharma, Meghna Birla, Abhay Rastogi, Abha Sharma, Sachin Khurana, Deepam Pushpam, Ishaan Gupta, Amber Rathore, Deepali Jain, Sunil Kumar, Sushmita Pathy, Rajiv Kaushal, Vanita Noronha, Kumar Prabhash, Aarati Karaba, Vijayshree Gauribidanur Raghavendrachar, Nagesh Muniyappa","doi":"10.1016/j.cllc.2025.02.014","DOIUrl":"https://doi.org/10.1016/j.cllc.2025.02.014","url":null,"abstract":"<p><strong>Background: </strong>Lung cancer (LC) is traditionally perceived as a disease primarily affecting the elderly. However, individuals under the age of 40 represent a rare subset, accounting for up to 6% of all LC cases. There is limited information about demographic, clinical, pathological, and molecular features and treatment outcomes of young-onset LC.</p><p><strong>Methods: </strong>In this study, we have analyzed the clinical, pathological, molecular, treatment, and survival outcome data of non-small-cell lung cancer patients δ 40 years of age treated at a tertiary care center in India. Additionally, we compared the in-house genomic data of young-onset LC and late-onset LC tested on a common targeted next-generation sequencing (NGS) panel.</p><p><strong>Results: </strong>A total of 133 patients were included, with a median age of 36 years (21-40 years). Females constituted 40.6% of total, and 79% were never smokers. Adenocarcinoma was the most common histology (85.7%), and oncogene fusions were common (ALK fusion in 34% and ROS1 in 7%). After a median follow-up of 39.2 months (95% CI 20.3-49.86), median overall survival was 26 months (95% CI 15.56-32.43) and median progression-free survival (of patients with stage 4 disease) was 6.53 months (95% CI 5.03-8.4). In-house NGS data reveals a striking enrichment of fusions (ALK and RET) in young-onset LC.</p><p><strong>Conclusion: </strong>Young-onset LC is a unique entity with a higher prevalence of targetable genomic alterations, especially oncogene fusions. All efforts should be made to identify the targetable alterations in this enriched population and implement targeted therapy.</p>","PeriodicalId":10490,"journal":{"name":"Clinical lung cancer","volume":" ","pages":""},"PeriodicalIF":3.3,"publicationDate":"2025-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143691170","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}